| --- | --- | |-----------|-----------------------------------------------------------------------| | | | | | | | | | | Selective | Inhibition of ALK‐2 Signaling Ameliorates Disease in a | | Novel | Model of Iron Refractory Iron Deficiency Anemia (IRIDA) | | | Thomas Backus Natalia Medeiros, Evan Lema, ffolliott | | | , Fisher, Jasbir Seehra, Jennifer Lachey | | | Keros Therapeutics, Lexington MA, USA | | | June 2020 | | | in Focus | | | | | | | Disclosure All listed authors are employees of and shareholder ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________ FORM 10-Q ________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39264 _______________________________________ ...